Oral L-Citrulline and ADMA in Pregnancy

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine if oral of L-citrulline (3 grams/day) for 3 weeks provided in mid-pregnancy to obese subjects will decrease the plasma ADMA/L-arginine ratio, lower maternal blood pressure, improve endothelial-dependent vascular function and peripheral vascular stiffness, and improve uterine artery Doppler resistance and flow.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Criteria

Inclusion Criteria:

• Pre-pregnancy body mass index greater than or equal to 30kg/m2

• Primiparity

• Singleton pregnancy

• Gestational age at randomization between 10 and 14 weeks based on clinical information and evaluation of earliest ultrasound

• Maternal age between 14 and 40 years

Exclusion Criteria:

• chronic hypertension

• pregestational diabetes on medication (insulin, glyburide)

• major fetal anomaly or demise

• planned termination of the pregnancy

• collagen vascular disease (autoimmune disease) on medication

• renal disease

• epilepsy or other seizure disorder

• active or chronic liver disease

• heart disease

• cigarette smoker

• known illicit drug or alcohol abuse during current pregnancy

• already taking L-citrulline as a supplement (1gram/day or more)